Q-omics provides the consensus-scored MIR3177 profile across patient tissues and cancer cell-line models. MIR3177 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR3177 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, MIR3177 RNA expression shows 12,906 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, BLCA, and LAML as cancer lineages where MIR3177 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3177 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3177 survival associations across molecular data types. MIR3177 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3177 RNA expression–survival associations across cancer types. High MIR3177 expression shows unfavorable associations in MESO, UVM, CHOL, STAD and LUSC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for MIR3177 RNA expression.
This table summarizes MIR3177 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3177. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3177 shows higher tumor expression in BLCA, KIRC, CHOL, STAD, ESCA and COAD. The BLCA box plot shows higher MIR3177 RNA expression in tumor versus normal tissue (log2 FC = +0.692, t-test p = .008).
This table shows molecular features associated with MIR3177 in patient tissues and cancer cell lines. In patient samples, MIR3177 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
